Citadel Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.92M	Sell	624,659 -3,605,340	-85%	-$13.9M	﹤0.01%	6142
2025 Q4	$17.3M	Buy	4,229,999 +2,881,315	+214%	+$14.3M	0.01%	2529
2025 Q3	$6.58M	Buy	1,348,684 +34,132	+3%	+$179K	0.01%	3883
2025 Q2	$6.65M	Sell	1,314,552 -1,341,159	-51%	-$6.59M	0.01%	3636
2025 Q1	$14M	Sell	2,655,711 -83,536	-3%	-$609K	0.01%	2438
2024 Q4	$18.5M	Buy	2,739,247 +2,505,024	+1,070%	+$16.8M	0.02%	2238
2024 Q3	$1.54M	Sell	234,223 -510,856	-69%	-$3.66M	﹤0.01%	6000
2024 Q2	$5.59M	Buy	745,079 +404,705	+119%	+$3.53M	0.01%	3578
2024 Q1	$3.39M	Buy	340,374 +303,880	+833%	+$3.38M	﹤0.01%	4577
2023 Q4	$360K	Sell	36,494 -266,596	-88%	-$1.9M	﹤0.01%	8781
2023 Q3	$2.32M	Sell	303,090 -434,668	-59%	-$4.34M	﹤0.01%	4954
2023 Q2	$5.51M	Buy	737,758 +132,243	+22%	+$925K	0.01%	3503
2023 Q1	$4.04M	Sell	605,515 -165,635	-21%	-$1.31M	﹤0.01%	4144
2022 Q4	$5.95M	Buy	771,150 +269,280	+54%	+$2.64M	0.01%	3579
2022 Q3	$5.34M	Buy	501,870 +194,498	+63%	+$1.97M	0.01%	3755
2022 Q2	$2.5M	Sell	307,372 -602,598	-66%	-$4.03M	﹤0.01%	5104
2022 Q1	$6.51M	Buy	909,970 +710,363	+356%	+$7.55M	0.01%	3671
2021 Q4	$3.42M	Buy	+199,607	New	+$3.76M	﹤0.01%	5085
2021 Q3	–	Hold	0	–	–	–	14666
2021 Q2	–	Hold	0	–	–	–	14440